{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:04Z","timestamp":1787020204382,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preeclampsia is a major pregnancy complication that results in significant maternal and infant mortality, most of which occurs in low and middle-income countries. The accurate and timely diagnosis of preeclampsia is critical in management of affected pregnancies to reduce maternal and fetal\/neonatal morbidity and mortality, yet difficulties remain in establishing the rigorous diagnosis of preeclampsia based on clinical parameters alone. Biomarkers that detect biochemical disease have been proposed as complements or alternatives to clinical criteria to improve diagnostic accuracy. This cohort study assessed the performance of several biomarkers, including glycosylated fibronectin (GlyFn), to rule-in or rule-out preeclampsia within 4\u2009weeks in a cohort of women at increased risk for preeclampsia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>151 women with risk factors for or clinical signs and symptoms of preeclampsia were selected from a prospective cohort. Maternal serum samples were collected between 20 and 37\u2009weeks of gestation. Clinical suspicion of preeclampsia was defined as presence of new-onset proteinuria, or clinical symptoms of preeclampsia. Subjects with a clinical diagnosis of preeclampsia at the time of enrollment were excluded. GlyFn, pregnancy-associated plasma protein-A2 (PAPPA2), placental growth factor (PlGF), and soluble fms-like tyrosine kinase-1 (sFlt-1) were measured by immunoassay. GlyFn was also determined using a rapid point-of care (POC) test format. Receiver-operating characteristic (ROC) curves derived from logistic regression analysis were used to determine the classification performance for each analyte.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>32 of 151 (21%) women developed a clinical diagnosis of preeclampsia within 4\u2009weeks. All biomarkers exhibited good classification performance [GlyFn (area under the curve (AUROC)\u2009=\u20090.94, 91% sensitivity, 86% specificity); PAPPA2 AUC\u2009=\u20090.92, 87% sensitivity, 77% specificity; PlGF AUC\u2009=\u20090.90, 81% sensitivity, 83% specificity; sFlt-1 AUC\u2009=\u20090.92, 84% sensitivity, 91% specificity. The GlyFn immunoassay and the rapid POC test showed a correlation of r\u2009=\u20090.966.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this prospective cohort, serum biomarkers of biochemical disease were effective in short-term prediction of preeclampsia, and the performance of GlyFn in particular as a POC test may meet the needs of rapid and accurate triage and intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-020-2809-2","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T13:06:01Z","timestamp":1582549561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5382-1353","authenticated-orcid":false,"given":"Evelyn A.","family":"Huhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Martinez De Tejada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soeren","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie M.","family":"Sage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles T.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Gravett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasa R.","family":"Nagalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Lapaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"issue":"3","key":"2809_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/j.semperi.2009.02.010","volume":"33","author":"L Duley","year":"2009","unstructured":"Duley L. The global impact of pre-eclampsia and Eclampsia. Semin Perinatol. 2009;33(3):130\u20137. https:\/\/doi.org\/10.1053\/j.semperi.2009.02.010.","journal-title":"Semin Perinatol"},{"issue":"4","key":"2809_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/AOG.0000000000000472","volume":"124","author":"S Lisonkova","year":"2014","unstructured":"Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph KS. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol. 2014;124(4):771\u201381. https:\/\/doi.org\/10.1097\/AOG.0000000000000472.","journal-title":"Obstet Gynecol"},{"issue":"9516","key":"2809_CR3","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S0140-6736(06)68397-9","volume":"367","author":"KS Khan","year":"2006","unstructured":"Khan KS, Wojdyla D, Say L, G\u00fclmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(06)68397-9.","journal-title":"Lancet"},{"issue":"6","key":"2809_CR4","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/S2214-109X(14)70227-X","volume":"2","author":"L Say","year":"2014","unstructured":"Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Heal. 2014;2(6):e323\u201333. https:\/\/doi.org\/10.1016\/S2214-109X(14)70227-X.","journal-title":"Lancet Glob Heal"},{"issue":"4","key":"2809_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.bpobgyn.2011.04.002","volume":"25","author":"T Firoz","year":"2011","unstructured":"Firoz T, Sanghvi H, Merialdi M, Von Dadelszen P. Pre-eclampsia in low and middle income countries. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):537\u201348. https:\/\/doi.org\/10.1016\/j.bpobgyn.2011.04.002.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"4","key":"2809_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.9745\/GHSP-D-15-00350","volume":"3","author":"S Hodgins","year":"2015","unstructured":"Hodgins S. Pre-eclampsia as underlying cause for perinatal deaths: time for action. Glob Heal Sci Pract. 2015;3(4):525\u20137. https:\/\/doi.org\/10.9745\/GHSP-D-15-00350.","journal-title":"Glob Heal Sci Pract"},{"issue":"apr15 7","key":"2809_CR7","doi-asserted-by":"publisher","first-page":"g2301","DOI":"10.1136\/bmj.g2301","volume":"348","author":"K. Bramham","year":"2014","unstructured":"Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ. 2014;348. https:\/\/doi.org\/10.1136\/bmj.g2301.","journal-title":"BMJ"},{"issue":"5","key":"2809_CR8","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/01.AOG.0000437382.03963.88","volume":"122","author":"American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy","year":"2013","unstructured":"American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122\u201331. https:\/\/doi.org\/10.1097\/01.AOG.0000437382.03963.88.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"2809_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.preghy.2014.02.001","volume":"4","author":"AL Tranquilli","year":"2014","unstructured":"Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97\u2013104. https:\/\/doi.org\/10.1016\/j.preghy.2014.02.001.","journal-title":"Pregnancy Hypertens"},{"issue":"7","key":"2809_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1701-2163(15)30533-8","volume":"36","author":"LA Magee","year":"2014","unstructured":"Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, SOGC. Hypertension guideline committee. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014;36(7):575\u20136. https:\/\/doi.org\/10.1016\/S1701-2163(15)30533-8.","journal-title":"J Obstet Gynaecol Can"},{"issue":"2","key":"2809_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1479-828X.2000.tb01136.x","volume":"40","author":"MA Brown","year":"2000","unstructured":"Brown MA, Hague WM, Higgins J, et al. The detection, investigation and management of hypertension in pregnancy: executive summary. Aust New Zeal J Obstet Gynaecol. 2000;40(2):133\u20138. https:\/\/doi.org\/10.1111\/j.1479-828X.2000.tb01136.x.","journal-title":"Aust New Zeal J Obstet Gynaecol"},{"issue":"8051","key":"2809_CR12","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S0140-6736(77)92661-7","volume":"310","author":"C.W.G. Redman","year":"1977","unstructured":"Redman CW, Denson KW, Beilin LJ, Bolton FG, Stirrat GM. Factor-VIII consumption in pre-eclampsia. Lancet (London, England). 1977;2(8051):1249\u20131252. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/73951. Accessed February 2, 2017.","journal-title":"The Lancet"},{"issue":"10022","key":"2809_CR13","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0140-6736(15)00070-7","volume":"387","author":"BWJ Mol","year":"2016","unstructured":"Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet (London, England). 2016;387(10022):999\u20131011. https:\/\/doi.org\/10.1016\/S0140-6736(15)00070-7.","journal-title":"Lancet (London, England)"},{"issue":"7","key":"2809_CR14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMoa031884","volume":"350","author":"RJ Levine","year":"2004","unstructured":"Levine RJ, Maynard SE, Qian C, et al. Circulating Angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672\u201383. https:\/\/doi.org\/10.1056\/NEJMoa031884.","journal-title":"N Engl J Med"},{"issue":"2","key":"2809_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1071\/RD12384","volume":"26","author":"K Macintire","year":"2014","unstructured":"Macintire K, Tuohey L, Ye L, et al. PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia. Reprod Fertil Dev. 2014;26(2):351\u20137. https:\/\/doi.org\/10.1071\/RD12384.","journal-title":"Reprod Fertil Dev"},{"issue":"4","key":"2809_CR16","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1161\/HYPERTENSIONAHA.114.03848","volume":"64","author":"Mark K. Santillan","year":"2014","unstructured":"Santillan MK, Santillan DA, Scroggins SM, et al. Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model. Hypertens (Dallas, Tex 1979). 2014;64(4):852\u2013859. doi:10.1161\/HYPERTENSIONAHA.114.03848","journal-title":"Hypertension"},{"issue":"6","key":"2809_CR17","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1161\/HYPERTENSIONAHA.114.03762","volume":"64","author":"Edwina H. Yeung","year":"2014","unstructured":"Yeung EH, Liu A, Mills JL, et al. Increased levels of copeptin before clinical diagnosis of preeclampsia. Hypertens (Dallas, Tex 1979). 2014;64(6):1362\u20131367. doi:10.1161\/HYPERTENSIONAHA.114.03762","journal-title":"Hypertension"},{"issue":"3","key":"2809_CR18","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/AOG.0b013e3182a0c88b","volume":"122","author":"JP Rasanen","year":"2013","unstructured":"Rasanen JP, Snyder CK, Rao PV, et al. Glycosylated Fibronectin as a first-trimester biomarker for prediction of gestational diabetes. Obstet Gynecol. 2013;122(3):586\u201394. https:\/\/doi.org\/10.1097\/AOG.0b013e3182a0c88b.","journal-title":"Obstet Gynecol"},{"issue":"NOV","key":"2809_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fmed.2018.00325","volume":"5","author":"EA Huhn","year":"2018","unstructured":"Huhn EA, Kreienb\u00fchl A, Hoffmann I, et al. Diagnostic accuracy of different soluble fms-like tyrosine Kinase 1 and placental growth factor cut-off values in the assessment of preterm and term preeclampsia: A gestational age matched case-control study. Front Med. 2018;5(NOV):325. https:\/\/doi.org\/10.3389\/fmed.2018.00325.","journal-title":"Front Med"},{"issue":"5","key":"2809_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1055\/s-0032-1316324","volume":"216","author":"M Voigt","year":"2012","unstructured":"Voigt M, Rochow N, Guthmann F, Hesse V, Schneider KTM, Schnabel D. Birth weight percentile values for girls and boys under consideration of maternal height. Z Geburtshilfe Neonatol. 2012;216(5):212\u20139. https:\/\/doi.org\/10.1055\/s-0032-1316324.","journal-title":"Z Geburtshilfe Neonatol"},{"issue":"2","key":"2809_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000365556","volume":"36","author":"E Gratac\u00f3s","year":"2014","unstructured":"Gratac\u00f3s E, Figueras F. Fetal growth restriction as a perinatal and long-term health problem: clinical challenges and opportunities for future (4P) fetal medicine. Fetal Diagn Ther. 2014;36(2):85. https:\/\/doi.org\/10.1159\/000365556.","journal-title":"Fetal Diagn Ther"},{"issue":"1","key":"2809_CR22","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ajog.2014.07.052","volume":"212","author":"J Rasanen","year":"2015","unstructured":"Rasanen J, Quinn MJ, Laurie A, et al. Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia. Am J Obstet Gynecol. 2015;212(1):82):e1\u20139. https:\/\/doi.org\/10.1016\/j.ajog.2014.07.052.","journal-title":"Am J Obstet Gynecol"},{"key":"2809_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/00401706.1964.10490181","volume":"6","author":"OJ Dunn","year":"1964","unstructured":"Dunn OJ. Multiple comparisons using rank sums. Technometrics. 1964;6:241\u201352.","journal-title":"Technometrics"},{"key":"2809_CR24","doi-asserted-by":"publisher","unstructured":"Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12. https:\/\/doi.org\/10.1186\/1471-2105-12-77.","DOI":"10.1186\/1471-2105-12-77"},{"issue":"6","key":"2809_CR25","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2215\/CJN.12081115","volume":"11","author":"E Phipps","year":"2016","unstructured":"Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin J Am Soc Nephrol. 2016;11(6):1102\u201313. https:\/\/doi.org\/10.2215\/CJN.12081115.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2809_CR26","unstructured":"Monte S. Biochemical markers for prediction of preclampsia: review of the literature. J Prenat Med 2011;5(3):69\u201377. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22439080. Accessed October 25, 2019."},{"issue":"5","key":"2809_CR27","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1161\/HYPERTENSIONAHA.111.00250","volume":"61","author":"Anne Cathrine Staff","year":"2013","unstructured":"Staff AC, Benton SJ, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertens (Dallas, Tex 1979). 2013;61(5):932\u2013942. doi:10.1161\/HYPERTENSIONAHA.111.00250","journal-title":"Hypertension"},{"issue":"7","key":"2809_CR28","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/pd.4397","volume":"34","author":"LC Poon","year":"2014","unstructured":"Poon LC, Nicolaides KH. First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn. 2014;34(7):618\u201327. https:\/\/doi.org\/10.1002\/pd.4397.","journal-title":"Prenat Diagn"},{"key":"2809_CR29","doi-asserted-by":"publisher","unstructured":"Kar M. Role of biomarkers in early detection of preeclampsia. J Clin Diagn Res. 2014;8(4):BE01\u2013BE04. https:\/\/doi.org\/10.7860\/JCDR\/2014\/7969.4261.","DOI":"10.7860\/JCDR\/2014\/7969.4261"},{"issue":"9","key":"2809_CR30","doi-asserted-by":"publisher","first-page":"23035","DOI":"10.3390\/ijms160923035","volume":"16","author":"P Wu","year":"2015","unstructured":"Wu P, Van Den Berg C, Alfirevic Z, et al. Early pregnancy biomarkers in pre-eclampsia: a systematic review and meta-analysis. Int J Mol Sci. 2015;16(9):23035\u201356. https:\/\/doi.org\/10.3390\/ijms160923035.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2809_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1414838","volume":"374","author":"H Zeisler","year":"2016","unstructured":"Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1414838.","journal-title":"N Engl J Med"},{"issue":"19","key":"2809_CR32","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1161\/CIRCULATIONAHA.113.003215","volume":"128","author":"Lucy C. Chappell","year":"2013","unstructured":"Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128(19):2121\u20132131. doi:10.1161\/CIRCULATIONAHA.113.003215.","journal-title":"Circulation"},{"issue":"4","key":"2809_CR33","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.116.08620","volume":"69","author":"Ulla Sovio","year":"2017","unstructured":"Sovio U, Gaccioli F, Cook E, Hund M, Charnock-Jones DS, Smith GCS. Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women. Hypertens (Dallas, Tex 1979). 2017;69(4):731\u2013738. doi:10.1161\/HYPERTENSIONAHA.116.08620","journal-title":"Hypertension"},{"issue":"8","key":"2809_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2352-4642(18)30129-9","volume":"2","author":"F Gaccioli","year":"2018","unstructured":"Gaccioli F, Sovio U, Cook E, Hund M, Charnock-Jones DS, Smith GCS. Screening for fetal growth restriction using ultrasound and the sFLT1\/PlGF ratio in nulliparous women: a prospective cohort study. Lancet Child Adolesc Heal. 2018;2(8):569\u201381. https:\/\/doi.org\/10.1016\/S2352-4642(18)30129-9.","journal-title":"Lancet Child Adolesc Heal"},{"issue":"1","key":"2809_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/uog.17301","volume":"49","author":"I Dragan","year":"2017","unstructured":"Dragan I, Georgiou T, Prodan N, Akolekar R, Nicolaides KH. Screening for pre-eclampsia using sFlt-1\/PlGF ratio cut-off of 38 at 30\u201337 weeks\u2019 gestation. Ultrasound Obstet Gynecol. 2017;49(1):73\u20137. https:\/\/doi.org\/10.1002\/uog.17301.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"2809_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/ki.2012.348","volume":"83","author":"A Rolfo","year":"2013","unstructured":"Rolfo A, Attini R, Nuzzo AM, et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int. 2013;83(1):177\u201381. https:\/\/doi.org\/10.1038\/ki.2012.348.","journal-title":"Kidney Int"},{"issue":"4","key":"2809_CR37","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1159\/000339935","volume":"74","author":"H Masuyama","year":"2012","unstructured":"Masuyama H, Nobumoto E, Okimoto N, Inoue S, Segawa T, Hiramatsu Y. Superimposed preeclampsia in women with chronic kidney disease. Gynecol Obstet Investig. 2012;74(4):274\u201381. https:\/\/doi.org\/10.1159\/000339935.","journal-title":"Gynecol Obstet Investig"},{"issue":"12","key":"2809_CR38","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1177\/0961203314529172","volume":"23","author":"GR de Jesus","year":"2014","unstructured":"de Jesus GR, de Jesus NR, Levy RA, Klumb EM. The use of angiogenic and antiangiogenic factors in the differential diagnosis of pre-eclampsia, antiphospholipid syndrome nephropathy and lupus nephritis. Lupus. 2014;23(12):1299\u2013301. https:\/\/doi.org\/10.1177\/0961203314529172.","journal-title":"Lupus"},{"issue":"4","key":"2809_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3109\/10641950903572282","volume":"29","author":"JL Van Der Merwe","year":"2010","unstructured":"Van Der Merwe JL, Hall DR, Wright C, Schubert P, Grov\u00e9 D. Are early and late preeclampsia distinct subclasses of the diseasewhat does the placenta reveal. Hypertens Pregnancy. 2010;29(4):457\u201367. https:\/\/doi.org\/10.3109\/10641950903572282.","journal-title":"Hypertens Pregnancy"},{"issue":"2","key":"2809_CR40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1081\/PRG-120021060","volume":"22","author":"P von Dadelszen","year":"2003","unstructured":"von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22(2):143\u20138. https:\/\/doi.org\/10.1081\/PRG-120021060.","journal-title":"Hypertens Pregnancy"},{"issue":"1","key":"2809_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.preghy.2011.08.117","volume":"2","author":"UB Knudsen","year":"2012","unstructured":"Knudsen UB, Kronborg CS, von Dadelszen P, et al. A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertens. 2012;2(1):8\u201315. https:\/\/doi.org\/10.1016\/j.preghy.2011.08.117.","journal-title":"Pregnancy Hypertens"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-020-2809-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12884-020-2809-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-020-2809-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T19:23:21Z","timestamp":1614021801000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-020-2809-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2809"],"URL":"https:\/\/doi.org\/10.1186\/s12884-020-2809-2","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"4 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CR and SN are shareholders in, and KS and SN are employees of, DiabetOmics, Inc. OL has acted as a consultant for Roche Diagnostics and has a pending patent related to the dynamics of the sFlt-1 or endoglin: PlGF ratio as an indicator for the prediction of postpartum HELLP syndrome, postpartum eclampsia, or postpartum preeclampsia (PCT\/EP2015\/051457). The other authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}